40 76

Cited 0 times in

Efficacy and safety of HT080 for lower urinary tract symptoms associated with benign prostatic hyperplasia: A study protocol for a randomized, double-blind, placebo-controlled trial

Authors
 Jungbin Song  ;  Seung Hwan Lee  ;  Hocheol Kim 
Citation
 MEDICINE, Vol.98(45) : e17848, 2019 
Journal Title
 MEDICINE 
ISSN
 0025-7974 
Issue Date
2019
MeSH
Adult ; Aged ; Cinnamomum aromaticum/chemistry* ; Double-Blind Method ; Humans ; Lower Urinary Tract Symptoms/drug therapy* ; Lower Urinary Tract Symptoms/etiology ; Male ; Medicine, Korean Traditional ; Middle Aged ; Plant Extracts/administration & dosage* ; Plant Extracts/adverse effects ; Prospective Studies ; Prostatic Hyperplasia/complications ; Prostatic Hyperplasia/drug therapy* ; Rosa/chemistry* ; Treatment Outcome
Abstract
BACKGROUND: Lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) are one of the most common conditions seen in middle-aged and elderly men and threaten their quality of life. Since conventional pharmacotherapy for LUTS/BPH can lead to sexual side effects, herbal therapies are widely used as complementary and alternative treatments worldwide. HT080 is an herbal extract of Cinnamomum cassia and Rosa Laevigata, both of which have been used to treat symptoms typically associated with BPH in traditional Asian medicine. The aims of this trial are to assess whether HT080 can alleviate LUTS/BPH in middle-aged and elderly men, and to investigate the safety of HT080. METHODS/DESIGN: A double-blind, randomized, placebo-controlled, two-arm parallel group trial will be conducted in men with moderate LUTS/BPH. A total of 100 eligible men aged 40 to 75 years with an International Prostate Symptom Score of 8 to 19 will be randomized in a 1:1 ratio and receive either HT080 (500 mg) or placebo twice a day for 12 weeks. All participants will be evaluated for efficacy and safety at baseline and weeks 6 and 12. The primary endpoint is the change in International Prostate Symptom Score between baseline and week 12. The secondary efficacy variables are uroflowmetry parameters (maximal urinary flow rate and post-void residual volume), serum prostate-specific antigen, testosterone, and dihydrotestosterone levels, the International Index of Erectile Function score, and participant-reported global response assessment scores. The safety assessments include adverse events, laboratory tests results, vital signs, and physical examination. DISCUSSION: This is a first-in human trial designed to investigate the efficacy and safety of HT080 among middle-aged and elderly men with LUTS/BPH. This prospective study with a double-blind randomized design will provide high-quality evidence supporting the use of HT080 for LUTS/BPH. TRIAL REGISTRATION: Korean Clinical Research Information Service (KCT0004286) Registered September 6, 2019.
Files in This Item:
T201904668.pdf Download
DOI
10.1097/MD.0000000000017848
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Lee, Seung Hwan(이승환) ORCID logo https://orcid.org/0000-0001-7358-8544
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/173451
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links